Wave Life Sciences Ltd. - Ordinary Shares (WVE) News
Filter WVE News Items
WVE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
WVE News Highlights
- WVE's 30 day story count now stands at 5.
- Over the past 22 days, the trend for WVE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about WVE are WAVE, ROSE and BIO.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 115% return over the last yearIt certainly might concern Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders to see the share price down 30% in just... |
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth ConsideringWave Life Sciences Ltd. (NASDAQ:WVE) price on Friday, January 13, rose 4.00% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.46. A look at the stock’s price movement, the close in the last trading session was $5.25, moving within a range at $5.13 and $5.695. The beta … Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth Considering Read More » |
How should investors view Wave Life Sciences Ltd. (WVE)?Wave Life Sciences Ltd. (NASDAQ:WVE) marked $5.25 per share on Thursday, down from a previous closing price of $5.26. While Wave Life Sciences Ltd. has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 93.73%, with highs and lows ranging from […] |
Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life SciencesAVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog. |
All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to BuyWave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
4 Drug Stocks That More Than Doubled This YearWe present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022. |
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing |
Wave Life Sciences Touts Encouraging Data From Duchenne Muscular Dystrophy StudyWave Life Sciences Ltd (NASDAQ: WVE) announced an update from the initial cohort of the Phase 1b/2a proof-of-concept study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. High muscle concentrations of WVE-N531 and exon skipping were observed six weeks after initiating biweekly multi-dosing at 10 mg/kg, achieving proof-of-concept in the study. Related: Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders. WVE |
Wave Life Sciences (WVE) Up 26% on Collaboration With GSKWave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets |